Clinical trials: Antibody
Advanced/Metastatic Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors
This study is a multi-center, open-label, dose-escalation, dose-expansion, and cohort-expansion first-in-human Phase 1/2 study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of…
- Trial name
- NCT07857135
- Testing
- SYS6088, Regorafenib, Ivonescimab
- Volunteers
- 140 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Advanced Unresectable Solid Tumors
Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable…
- Trial name
- NCT04894825
- Testing
- M108
- Where
- China
- Volunteers
- 152 people
- Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
Pertussis
Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)
The purpose of this study is to evaluate the persistence of immune response against the three pertussis antigens (anti- pertussis toxoid (PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN)) in subjects who…
- Trial name
- NCT02382913
- Testing
- aP booster, TdaP booster, Licensed TdaP booster (Boostrix®)
- Where
- Belgium
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Novartis
Gastric Neoplasms, Pancreatic Neoplasms
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and tolerability of ASG-5ME and identify the maximum tolerated dose in patients with pathologically confirmed metastatic pancreatic…
- Trial name
- NCT01166490
- Testing
- ASG-5ME
- Where
- 7 sites in United States
- Volunteers
- 51 people
- Sponsor
- Seagen Inc.
ANCA Associated Vasculitis (AAV)
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
- Trial name
- NCT06868290
- Testing
- Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
- Where
- 39 sites in United States, Brazil and 6 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
ACUTE MYELOID LEUKEMIA; AML
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
This is a phase 1b/2 study. All patients are diagnosed with Acute Myeloid Leukemia (AML), Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
- Trial name
- NCT06387420
- Testing
- AK117, Azacitidine, Venetoclax
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Akeso
Influenza A H1N1
Study of SAB-176 in Healthy Adult Participants
Healthy adult participants will be challenged with the H1N1 Influenza virus and then treated with either SAB-176 or placebo.
- Trial name
- NCT04850898
- Testing
- SAB-176
- Where
- United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.
Advanced Solid Tumors
Study of ABT-700 in Subjects With Advanced Solid Tumors
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-700 in subjects with advanced solid tumors that may have MET amplification or c-Met overexpression.
- Trial name
- NCT01472016
- Testing
- ABT-700, docetaxel, FOLFIRI
- Volunteers
- 74 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
13-valent Pneumococcal Vaccine, Immunization
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
This is an open-label study (a study in which the doctors and participants know which drug or vaccine is being administered) in children who previously received a 4-dose series of a pneumococcal conjugate vaccine (PnC) during…
- Conditions
- 13-valent Pneumococcal Vaccine, Immunization, Safety, Antibody Response
- Trial name
- NCT01026038
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 25 sites in France
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Pfizer
Osteoarthritis
Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip
The purpose of this study is to investigate the analgesic efficacy and safety of tanezumab added on to diclofenac SR in patients with osteoarthritis of the knee or hip currently experiencing partial benefit from, and are…
- Trial name
- NCT00864097
- Testing
- tanezumab, diclofenac
- Where
- 77 sites in Austria, France and 8 more
- Volunteers
- 607 people
- Sponsor
- Pfizer
Ulcerative Colitis, Digestive System Diseases
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
The purpose of this study is to determine the safety and tolerability of administration of multiple ascending doses of KHK4083 and to select the highest dose tolerated by subjects with moderately active Ulcerative Colitis (UC)…
- Conditions
- Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis
- Trial name
- NCT02647866
- Testing
- KHK4083
- Where
- 23 sites in United States, Czechia and 5 more
- Volunteers
- 66 people
- Sponsor
- Kyowa Kirin, Inc.
Acute Myeloid Leukemia
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
The study will examine the safety profile of SGN-CD123A. The study will test increasing doses of SGN-CD123A given every 3 weeks to patients.
- Trial name
- NCT02848248
- Testing
- SGN-CD123A
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Seagen Inc.
Epithelial Ovarian Cancer
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with…
- Trial name
- TREVI-OC-02 (NCT07851025)
- Testing
- Torvutatug samrotecan, Bevacizumab
- Where
- 186 sites in United States, Argentina and 22 more
- Volunteers
- 950 people
- Sponsor
- AstraZeneca
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
This study will evaluate the safety and efficacy of omalizumab for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with Cystic Fibrosis aged 12 years and older.
- Trial name
- NCT00787917
- Testing
- Omalizumab, Itraconazole
- Where
- 10 sites in Belgium, Germany and 3 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Rheumatoid
Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients
This study will examine the safety and tolerability, PK and PD of subcutaneously administered GSK1841157 in patients with RA on stable dose Methotrexate.
- Trial name
- NCT00686868
- Testing
- ofatumumab
- Where
- 17 sites in United States, Australia and 7 more
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
High Risk Stage III Melanoma
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
The purpose of the study is to determine if ipilimumab is effective in preventing or delaying recurrence and prolongs survival after complete resection of high risk stage III melanoma
- Trial name
- NCT00636168
- Testing
- ipilimumab
- Where
- 97 sites in United States, Australia and 17 more
- Volunteers
- 1,211 people
- Sponsor
- Bristol-Myers Squibb
Allergic Rhinitis
Study of CM310 in Patients With Allergic Rhinitis
This study is a multicenter, single arm, open-label phase II clinical study mainly evaluating the safety of CM310 in patients with allergic rhinitis.
- Trial name
- NCT05908721
- Testing
- CM310
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Keymed Biosciences Co.Ltd
Advanced Gastrointestinal Tumors
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
The purpose of this study is to investigate the safety and determine the maximum tolerated dose of TAS-102 administered in combination with CPT-11 in patients with advanced gastrointestinal tumors.
- Trial name
- NCT01916447
- Testing
- TAS-102, CPT-11, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Taiho Oncology, Inc.
COVID-19 Pneumonia
Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity, safety and antibody persistence of the third dose (booster) of Covid-19 vaccine in patients aged 60 years or older with hypertension and/or diabetes.
- Trial name
- NCT05104333
- Testing
- Covid-19 vaccine (0-1-4 schedule), Covid-19 vaccine (0-1-6 schedule)
- Where
- 5 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Neoplasms
A Study of RO5458640 in Patients With Advanced Solid Tumors
This multicenter, open-label, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO5458640 in patients with advanced solid tumors.
- Trial name
- NCT01383733
- Testing
- RO5458640
- Where
- 4 sites in Canada, Denmark and 1 more
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.